All In Biotech

NDA 209195 · Gilead Sciences INC

Vosevi

Sofosbuvir, Velpatasvir, Voxilaprevir · Oral · Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor; Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus NS3/4A Protease Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 15, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 18, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

343

110 Phase 3, 6 recruiting

FAERS reports

1,086

405 serious, 35 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with VOSEVI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAA) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...

What it is approved for

From the label in effect Jul 14, 2025.

VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14) ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have ( 1 , 2.2 , 14 ): genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

Mechanism: VOSEVI is a fixed-dose combination of sofosbuvir, velpatasvir, and voxilaprevir which are DAA agents against the hepatitis C virus [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 15, 2019 Supplement 3 · Efficacy LetterLabel
  • Jul 18, 2017 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
  • VOSEVI · SOFOSBUVIR 400MG; VELPATASVIR 100MG; VOXILAPREVIR 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sofosbuvir" as an intervention, any sponsor and status, largest first.

All 343 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue197
  • headache134
  • treatment failure115
  • drug ineffective108
  • nausea104
  • hepatitis c91
  • diarrhoea86
  • vomiting36
  • insomnia29
  • abdominal discomfort23
  • hepatocellular carcinoma22
  • product dose omission20

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201780
2018363
2019275
2020133
202172
202246
202340
202419
202543
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vosevi (Sofosbuvir/Velpatas/Voxilaprev)

2024 spending

$45.2M

Beneficiaries

711

1,849 claims

Per beneficiary

$63,513

$857.57 per unit

View as table
YearSpending
2020$67,125,607
2021$58,255,793
2022$49,927,569
2023$46,336,417
2024$45,158,008

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 454 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.